Analysis of Semaglutide Peptide Biotherapeutics by LC/Q-TOF
Sommaire
Overviewpp. 1-2
Introduces peptide biotherapeutics and GLP-1 receptor agonists like semaglutide
Specp. 3
Lists LC/Q-TOF source and acquisition parameter values
Procedurep. 4
Compares chromatograms of semaglutide across seven columns
Procedurep. 5
Compares TFA and FA ion-pair reagents for resolution
Procedurep. 6
Confirms semaglutide identity via LC/MS data analysis
p. 2table, 7 rows
p. 2table, 7 rows
p. 3table, 7 rows
p. 3table, 7 rows
Table 1. LC-UV method conditions.
Parameter
Value
Column
(A) AdvanceBio Peptide Plus, 4.6 × 150 mm
(B) PLRP-S 8 µm 100 Å, 4.6 × 250 mm
(C) PLRP-S 8 µm 300 Å, 4.6 × 250 mm
(D) Polaris Amide C18, 5 µm, 4.6 × 250 mm
(E) Polaris C18-A, 5 µm, 4.6 × 250 mm
(F) AdvanceBio Peptide Mapping, 4.6 × 150 mm
(G) Pursuit C18, 5 µm, 4.6 × 250 mm
Mobile Phase
Eluent A1: 0.1% TFA in Water
Eluent B1: 0.1% TFA in ACN
Eluent A2: 0.1% FA in Water
Eluent B2: 0.1% FA in ACN
Flow Rate
1.0 mL/min
Column Temperature
25 °C
Injection Volume
10 µL
Detection
UV, 220 nm
Total Run Time
30 minutes
Table 1. LC-UV method conditions.
Parameter
Value
Column
(A) AdvanceBio Peptide Plus, 4.6 × 150 mm
(B) PLRP-S 8 µm 100 Å, 4.6 × 250 mm
(C) PLRP-S 8 µm 300 Å, 4.6 × 250 mm
(D) Polaris Amide C18, 5 µm, 4.6 × 250 mm
(E) Polaris C18-A, 5 µm, 4.6 × 250 mm
(F) AdvanceBio Peptide Mapping, 4.6 × 150 mm
(G) Pursuit C18, 5 µm, 4.6 × 250 mm
Mobile Phase
Eluent A1: 0.1% TFA in Water
Eluent B1: 0.1% TFA in ACN
Eluent A2: 0.1% FA in Water
Eluent B2: 0.1% FA in ACN
Flow Rate
1.0 mL/min
Column Temperature
25 °C
Injection Volume
10 µL
Detection
UV, 220 nm
Total Run Time
30 minutes
Table 4. Column characteristics.
Product Name
Pore Size (Å)
Particle Size (µm)
Particle Type
Bonding Chemistry
Dimensions (mm)
AdvanceBio Peptide Mapping
120
2.7
Superficially porous
Endcapped C18
4.6 × 150
AdvanceBio Peptide Plus
120
2.7
Superficially porous
Endcapped C18 with charged surface modification
4.6 × 150
PLRP-S
100
8
Fully porous
Polystyrene/divinylbenzene
4.6 × 250
PLRP-S
300
8
Fully porous
Polystyrene/divinylbenzene
4.6 × 250
Polaris Amide C18
180
5
Fully porous
Amide modified C18
4.6 × 250
Polaris C18-A
180
5
Fully porous
C18 Type A
4.6 × 250
Pursuit C18
200
5
Fully porous
Endcapped C18
4.6 × 250
Table 4. Column characteristics.
Product Name
Pore Size (Å)
Particle Size (µm)
Particle Type
Bonding Chemistry
Dimensions (mm)
AdvanceBio Peptide Mapping
120
2.7
Superficially porous
Endcapped C18
4.6 × 150
AdvanceBio Peptide Plus
120
2.7
Superficially porous
Endcapped C18 with charged surface modification
4.6 × 150
PLRP-S
100
8
Fully porous
Polystyrene/divinylbenzene
4.6 × 250
PLRP-S
300
8
Fully porous
Polystyrene/divinylbenzene
4.6 × 250
Polaris Amide C18
180
5
Fully porous
Amide modified C18
4.6 × 250
Polaris C18-A
180
5
Fully porous
C18 Type A
4.6 × 250
Pursuit C18
200
5
Fully porous
Endcapped C18
4.6 × 250
Engineering Facts
13 facts · every claim linked to a page
Selection
TFA is the standard ion-pair reagent for crude peptide HPLC, but FA is preferred for LC/MS impurity identification because it causes less ion suppression.
Determines which mobile phase modifier to choose depending on whether UV quantification or MS identification is the goal.
Source
“to identify the impurity peaks in an LC/MS method, formic acid (FA) is the preferred mobile phase modifier, as the weaker acid causes less ion suppression.”
Selection
FA forms a less hydrophobic ion pair and suppresses nonspecific interactions less effectively, so resolution can suffer compared to TFA.
Warns that switching to FA for MS compatibility may degrade chromatographic resolution and require column chemistry compensation.
Source
“FA is less effective at suppressing nonspecific interactions, and creates a less hydrophobic (and therefore less retentive) ion pair with the peptide.”
Selection
The 250 mm columns were deliberately chosen because the same chemistries are available in preparative dimensions, enabling scale-up.
Guides column selection when analytical methods must later be transferred to preparative purification.
Source
“the 250 mm long columns used for this work (PLRP-S 100 Å and 300 Å, Polaris and Pursuit) were chosen specifically because they are also available in preparative dimensions.”
Operation
Thermal degradation stress conditions were 85 °C for 60 minutes, which is the reference protocol for generating impurity profiles.
Defines the stress-test protocol needed to reproduce the impurity profile used for column comparison.
Source
“Thermal degradation was performed by heating to 85 °C for 60 minutes.”
Safety
Carryover is a specific hazard for fatty-acid-modified peptides, so blank gradient injections must be run after each sample.
Requires adding blank runs to the sequence to avoid false impurity peaks from carryover.
Source
“followed by a blank gradient to check for signs of carryover (a potential hazard with peptides that are modified with fatty acid side chain groups).”
Performance
The two superficially porous columns were 150 mm while all others were 250 mm, so retention comparisons across columns are not length-normalized.
Prevents misinterpreting retention time differences as chemistry effects when column length differs.
Source
“the two columns packed with superficially porous materials were 150 mm long, compared to the other columns which were all 250 mm long.”
Selection
Under FA conditions, residual acidic silanols cause peak tailing on silica columns unless the bonding chemistry carries residual positive charge.
Explains why charged-surface or amide-modified C18 chemistries should be selected for FA-based peptide methods.
Source
“the peak shape is inferior on several columns as a result of interactions between basic side chain residues of the peptide and residual acidic silanols on the surface of the silica stationary phase, leading to broader peaks and increased tailing.”
Selection
AdvanceBio Peptide Plus, Polaris Amide C18 and Polaris C18-A gave good peak shapes in FA due to residual positive charge in the bonding.
Narrows column shortlist for formic acid peptide separations to chemistries with positive surface charge.
Source
“The key difference with these materials is the presence of residual positive charge in the bonding chemistry, which helps prevent undesirable secondary interactions that result in increased tailing on other columns.”
Selection
AdvanceBio Peptide Plus was selected for LC/MS with FA because it retained excellent resolution in FA, unlike Polaris Amide C18 which lost some resolution.
Supports choosing this column when the method must be MS-compatible with formic acid.
Source
“For this reason, the AdvanceBio Peptide Plus column was chosen for LC/MS analysis using formic acid as the ion-pair reagent.”
Selection
Wider pore size (300 Å vs 100 Å) improves resolution for longer or modified peptide sequences by reducing mass transfer restriction.
Justifies selecting wider-pore media for modified or longer peptides rather than defaulting to small-pore columns.
Source
“Larger pores do not restrict the mass transfer in and out of the pores as much as smaller pore sized columns, which can then lead to sharper peaks.”
Performance
The 300 Å PLRP-S column clearly resolved the degraded sample better than the 100 Å version of the same chemistry.
Provides direct evidence that pore size selection affects impurity resolution for this analyte.
Source
“The resolution was clearly improved on the wider pore 300 Å column.”
Operation
LC/MS confirmation used a 2.1 × 150 mm AdvanceBio Peptide Plus column at 0.21 mL/min with the sample thermostat at 7 °C.
Specifies the autosampler temperature needed to keep the peptide sample stable during the MS run.
Source
“Thermostat 7 °C”
Performance
Identity was confirmed by the charge-state envelope [M+3H]3+ to [M+6H]6+ matching the 4,113.58 Da full-length sequence.
Gives the expected m/z values an engineer needs to verify sequence confirmation in the Q-TOF method.
Source
“the data clearly confirms the identity of the molecule with the expected [M + 3H]3+ at 1,372.05, [M + 4H]4+ at 1,029.29, [M + 5H]5+ at 823.63, and [M + 6H]6+ at 686.53”